Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis In Neurology Neuroimmunology & Neuroinflammation
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis In Neurology Neuroimmunology & Neuroinflammation
Immunic宣佈公佈Vidofludimus鈣治療神經病學神經免疫學和神經炎症復發緩解型多發性硬化症的2期重點試驗的擴展數據
- 30 mg and 45 mg Daily Doses of Vidofludimus Calcium Suppressed Development of Gadolinium-Enhancing Lesions by 78% and 74% Compared to Pooled Placebo at 24 Weeks.
- Improvements in Serum Neurofilament Light Chain Consistent with Recently Announced Interim Phase 2 CALLIPER Data in Progressive Multiple Sclerosis.
- Twin Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis and Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis Remain Underway.
- 與24周的合併安慰劑相比，每天服用30毫克和45毫克的Vidofludimus鈣可抑制鎵增強病變的發育78％和74％。
- 血清神經絲輕鏈的改善與最近公佈的進行性多發性硬化症中期第二階段CALLIPER數據一致。
- 複發性多發性硬化症的三期 ENSURE 試驗和進行性多發性硬化症的 2 期 CALLIPER 試驗仍在進行中。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。